Johannes van Houte, an officer at Nurix Therapeutics, Inc., has sold 4,769 shares of the company's common stock. This transaction, filed with the SEC on November 4, 2026, is valued at approximately $123,135. Such insider sales can provide insights into the company's internal dynamics and may influence investor perceptions.

Background

Nurix Therapeutics, Inc. is a company in the pharmaceutical preparations industry, specifically classified under SIC code 2834. The firm is based in Brisbane, California, and operates under the central index key (CIK) 0001549595. Recent filings indicate ongoing activities, with the latest being this Form 144 submission on November 4, 2026.

What the Filing Says

"Johannes van Houte sold 4,769 shares of common stock on November 4, 2026."

The filing details that van Houte acquired these shares as restricted stock units on October 30, 2026. The sale was executed through Morgan Stanley Smith Barney LLC, a well-known brokerage firm.

Impact

This sale may have implications for Nurix Therapeutics' stakeholders, including investors and analysts who monitor insider trading activities. Such transactions can signal the confidence or lack thereof that executives have in their company's future performance.

What's Next

The filing does not say what happens next.

Additional Details

In the filing, it is noted that Johannes van Houte sold an additional 2,834 shares of common stock on the same day he acquired the 4,769 shares, resulting in gross proceeds of approximately $74,474.97. This suggests that van Houte has been actively managing his holdings in the company.

The total number of outstanding shares for Nurix Therapeutics is reported to be 109,249,814, indicating the scale of the company's equity structure. The shares are traded on the NASDAQ exchange, which is a significant platform for technology and biotech companies.

Company Information

Nurix Therapeutics, Inc. was formerly known as Nurix, Inc., having undergone a name change on May 9, 2012. The company is incorporated in Delaware and has a fiscal year ending on November 30. The business address for Nurix is located at 1600 Sierra Point Parkway, Brisbane, CA 94005, with a contact phone number of (415) 660-5320.

Insider Trading Context

The filing also indicates that van Houte adopted a trading plan on February 3, 2026, which may provide a structured approach to his stock transactions. Such plans are often established to comply with insider trading regulations while allowing executives to manage their stock holdings without the appearance of impropriety.